Survival and standards of care in Duchenne muscular dystrophy (DMD) have evolved substantially, reshaping the clinical journey from early childhood into adulthood. This symposium will explore how improvements in life expectancy have increased the importance of coordinated, multidisciplinary care across all disease stages. Expert faculty will examine the role of the multidisciplinary team in managing the growing complexity of Duchenne, highlighting practical approaches to optimising long-term outcomes.
The session will also review the long-term benefits and recognised limitations of corticosteroid therapy in Duchenne, drawing on key clinical evidence. Finally, emerging data on the evolving standard of care regimens will be discussed, with a focus on their potential impact on long-term disease trajectory as well as clinically relevant outcomes such as growth and skeletal health. Together, these perspectives aim to challenge current assumptions and stimulate discussion on whether—and how—we may be beginning to change the long-term trajectory of Duchenne.